TheraRadar
← Back
Data updated: Mar 29, 2026

CORSTASIS THERAP

CardiovascularGastroenterology
Pharma

CORSTASIS THERAP is a pharmaceutical company focused on Cardiovascular, Gastroenterology. Key products include ENBUMYST.

2025
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

ENBUMYST
bumetanide
Cardiovascular
5 indications · 2025

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

ENBUMYST 2025-09-12
Type 3 - New Dosage Form
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 50%
1 drugs
Gastroenterology 50%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

BAUSCH specialty
Cardiovascular, Gastroenterology
APOTHECON specialty
Cardiovascular, Gastroenterology
VALIDUS PHARMS specialty
Cardiovascular, Gastroenterology
WAYLIS THERAP big-pharma
Cardiovascular, Gastroenterology
WARNER CHILCOTT LLC specialty
Cardiovascular, Gastroenterology